Alkermes PLC (ALKS) Receives "Neutral" Rating from Cantor Fitzgerald
's stock had its "neutral" rating restated by analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $51.00 target price on the stock.
from Biotech News
0 Comments